Procept Biorobotics Corp (PRCT) - Net Assets
Based on the latest financial reports, Procept Biorobotics Corp (PRCT) has net assets worth $380.28 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($511.54 Million) and total liabilities ($131.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Procept Biorobotics Corp carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $380.28 Million |
| % of Total Assets | 74.34% |
| Annual Growth Rate | 68.9% |
| 5-Year Change | 559.81% |
| 10-Year Change | N/A |
| Growth Volatility | 125.89 |
Procept Biorobotics Corp - Net Assets Trend (2019–2024)
This chart illustrates how Procept Biorobotics Corp's net assets have evolved over time, based on quarterly financial data. Also explore PRCT asset base for the complete picture of this company's asset base.
Annual Net Assets for Procept Biorobotics Corp (2019–2024)
The table below shows the annual net assets of Procept Biorobotics Corp from 2019 to 2024. For live valuation and market cap data, see PRCT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $402.22 Million | +43.27% |
| 2023-12-31 | $280.75 Million | +42.46% |
| 2022-12-31 | $197.07 Million | -26.22% |
| 2021-12-31 | $267.09 Million | +338.14% |
| 2020-12-31 | $60.96 Million | +108.55% |
| 2019-12-31 | $29.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Procept Biorobotics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39733600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $114.00K | 0.03% |
| Other Components | $948.09 Million | 235.71% |
| Total Equity | $402.22 Million | 100.00% |
Procept Biorobotics Corp Competitors by Market Cap
The table below lists competitors of Procept Biorobotics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VIA Technologies Inc
TW:2388
|
$1.38 Billion |
|
Kinnevik Investment AB ser. B
ST:KINV-B
|
$1.38 Billion |
|
Nextdecade Corp
NASDAQ:NEXT
|
$1.38 Billion |
|
Cogeco Communications Inc
TO:CCA
|
$1.38 Billion |
|
Atalaya Mining Ltd
F:E5S1
|
$1.38 Billion |
|
Cheil Worldwide
KO:030000
|
$1.38 Billion |
|
Chongqing Department Store Co Ltd
SHG:600729
|
$1.38 Billion |
|
NÜRNBERGER Beteiligungs-AG
F:NBG6
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Procept Biorobotics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 280,752,000 to 402,220,000, a change of 121,468,000 (43.3%).
- Net loss of 91,413,000 reduced equity.
- Share repurchases of 4,527,000 reduced equity.
- New share issuances of 164,523,000 increased equity.
- Other comprehensive income increased equity by 30,000.
- Other factors increased equity by 52,855,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-91.41 Million | -22.73% |
| Share Repurchases | $4.53 Million | -1.13% |
| Share Issuances | $164.52 Million | +40.9% |
| Other Comprehensive Income | $30.00K | +0.01% |
| Other Changes | $52.85 Million | +13.14% |
| Total Change | $- | 43.27% |
Book Value vs Market Value Analysis
This analysis compares Procept Biorobotics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 28.30x to 3.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.87 | $24.63 | x |
| 2020-12-31 | $1.73 | $24.63 | x |
| 2021-12-31 | $16.21 | $24.63 | x |
| 2022-12-31 | $4.44 | $24.63 | x |
| 2023-12-31 | $5.94 | $24.63 | x |
| 2024-12-31 | $7.72 | $24.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Procept Biorobotics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -40.72%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.33x
- Recent ROE (-22.73%) is above the historical average (-59.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -143.60% | -680.42% | 0.10x | 2.12x | $-44.90 Million |
| 2020 | -86.97% | -687.04% | 0.06x | 2.07x | $-59.12 Million |
| 2021 | -22.41% | -173.62% | 0.10x | 1.26x | $-86.56 Million |
| 2022 | -44.22% | -116.18% | 0.24x | 1.57x | $-106.86 Million |
| 2023 | -37.72% | -77.76% | 0.34x | 1.44x | $-133.97 Million |
| 2024 | -22.73% | -40.72% | 0.42x | 1.33x | $-131.63 Million |
Industry Comparison
This section compares Procept Biorobotics Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,555,245,291
- Average return on equity (ROE) among peers: -57.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Procept Biorobotics Corp (PRCT) | $380.28 Million | -143.60% | 0.35x | $1.38 Billion |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $1.47 Billion | -46.29% | 2.07x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $15.99 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.10 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $125.55 Million |
About Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Rob… Read more